Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alder Biopharmaceuticals, Inc. |
---|---|
Information provided by: | Alder Biopharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00867516 |
The purpose of this study is to determine the safety and efficacy of ALD518 in three different doses in patients who have not had an adequate response to methotrexate.
Condition | Intervention | Phase |
---|---|---|
Arthritis, Rheumatoid |
Biological: ALD518 Biological: Infusion without ALD518` |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate |
Enrollment: | 127 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
ALD518 80 mg
|
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
|
2: Experimental
ALD518 160 mg
|
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
|
3: Experimental
ALD518 320 mg
|
Biological: ALD518
Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
|
4: Placebo Comparator
No ALD518
|
Biological: Infusion without ALD518`
250 cc Normal saline IV over one hour Weeks 1 and 8.
|
This will be a phase II, parallel-group, double-blind, randomized, placebo-controlled study of ALD518 in patients with active RA with an inadequate response to methotrexate.
Enrolled patients will be screened within a 4-week period (Day -35 to -7). within a 12-day period (Day-14 to -3) before initial dosing on Day 1 patients will be randomized to one of the following four treatment groups: Group A: 2x ALD518 80 mg Group B: 2x ALD518 160 mg Group C: 2x ALD518 320 mg Group D: 2x placebo
In all treatment groups patients will continue to take a stable dose of methotrexate.
There will be a total of 11 visits. The total duration of the patient study participation will be approximately 16 weeks (excluding the screening period).
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Rheumatology Research Associates | |
Ottawa, Ontario, Canada, KIH IA2 | |
K-W Musculoskeletal Research, Inc. | |
Kitchener, Ontario, Canada, N2M 5N6 | |
Georgia | |
V. Tsitlanadze Scientific Practical Centre of Rheumatology | |
Tbilisi, Georgia, 0102 | |
Medulla Chemotherapy and Immunotherapy Clinic | |
Tbilisi, Georgia, 0186 | |
India | |
Krishna Institute of Medical Sciences Ltd. | |
Secunderabad, India, 500 003 | |
St. John's Medical College Hospital | |
Bangalore, India, 560 034 | |
India, Bangalore | |
Chanre Rheumatology and Immunology Center and Research | |
Malleshwaram, Bangalore, India, 560 003 | |
India, Belgaum | |
KLE Society Hospital and Medical Research Centre | |
Nehru Nagar, Belgaum, India, 590 010 | |
India, Nagpur | |
Sushrut Hospital, Research Centre & Post Graduate Institute of Orthopaedics | |
Ramadaspeth, Nagpur, India, 440 010 | |
Poland | |
Szezecin Clinic of Rheumatology and Internal Diseases | |
Szczecin, Poland, 71-252 | |
Provincional Rheumatological Complex named after Dr Jadwiga Titz-Kosko | |
Sopot, Poland, 81-759 | |
Nonpublic Centre of Medical Care Reumed | |
Lublin, Poland, 26-607 | |
NOVAMED - Medical Center of Poznan | |
Poznan, Poland, 60-773 | |
Miriada Center Private Clinic of Professor Sierakowski | |
Bialystok, Poland, 15-297 | |
Russian Federation | |
Regional Clinical Hospital of War Veterans | |
Kemerovo, Russian Federation, 650099 | |
Institute of Clinical and Experimental Lymphology | |
Novosibirsk, Russian Federation, 630117 | |
Tomsk Regional Clinical Hospital | |
Tomsk, Russian Federation, 634063 | |
Ryazan Regional Clinical Cardiologic Dispensary | |
Ryazan, Russian Federation, 390026 | |
Saint-Petersburg State Medical Academy named after I. I. Mechnikov | |
Saint-Petersburg, Russian Federation, 195067 | |
Saint Petersburg Medical Academy of Postgraduate Study | |
Saint-Petersburg, Russian Federation, 191015 | |
Regional War Veterans' Hospital | |
Saratov, Russian Federation, 410002 | |
City Hospital #26 | |
Saint Petersburg, Russian Federation, 196247 | |
Tula Regional Clinical Hospital | |
Tula, Russian Federation, 300053 | |
Clinical Hospital of Emergency Care named after N.V. Solovyev | |
Yaroslavl, Russian Federation, 150003 | |
Serbia | |
Institute of Rheumatology | |
Belgrade, Serbia, 11000 | |
Institute of Rheumatology | |
Belgrade, Serbia, 11000 | |
Institute for Rehabilitation and Treatment Niska Banja | |
Niska Banja, Serbia, 18205 | |
Institute of Rheumatology | |
Belgrade, Serbia, 11000 |
Study Director: | Jeffrey Smith, MD, FRCP | Alder BioPharmaceuticals |
Responsible Party: | Alder Biopharmaceuticals, Inc ( Jeffrey T L Smith, MD FRCP ) |
Study ID Numbers: | ALD518-CLIN-003 |
Study First Received: | March 20, 2009 |
Last Updated: | May 11, 2009 |
ClinicalTrials.gov Identifier: | NCT00867516 History of Changes |
Health Authority: | Canada: Health Canada; Georgia: Ministry of Health; Russia: Ministry of Health and Social Development of the Russian Federation; Serbia and Montenegro: Agency for Drugs and Medicinal Devices; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; India: Drugs Controller General of India |
Autoimmune Diseases Musculoskeletal Diseases Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Methotrexate Rheumatic Diseases |
Autoimmune Diseases Immune System Diseases Musculoskeletal Diseases Joint Diseases |
Arthritis Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases |